Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2024
Reporting Period: Event date February 9, 2024; Report signed February 12, 2024.
Context: The filing reports the resolution of a legal dispute regarding stock options and partnership agreements through a settlement agreement.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific legal settlement and the issuance of equity securities.
Material Changes and Settlement Details
The Company entered into a Settlement Agreement and mutual release with Dr. Elliot Lander, Saralee Berman (Trustee), and Cell Surgical Network, Inc. to resolve a dispute filed in March 2022 regarding the validity of 1,248,600 vested stock options. As consideration for the full release and dismissal of claims, the Company agreed to the following:
- Restricted Shares: Issuance of 200,000 restricted shares of common stock.
- Warrants: Issuance of 400,000 warrants to purchase restricted shares.
- Warrant Terms: Exercise price of $1.32 per share; exercisable for 5 years from the date of issuance.
- Piggy-back Rights: Physicians granted piggy-back registration rights, subject to the Company's discretion to refuse registration if it adversely affects capital raising.
The securities were issued to an accredited investor under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the dismissal of the lawsuit (Lander v. Calidi Biotherapeutics, Inc.) and the execution of the settlement. No forward-looking guidance or outlook regarding future financial performance is provided in this document.
Risks and Contingencies: The primary risk addressed was the ongoing litigation regarding stock options, which has now been resolved. A potential future contingency involves the Company's right to refuse registration of the settlement shares if it determines such registration would hinder capital raising efforts.
Investor Verification Checklist
- Verify the exact number of shares issued (200,000) and warrants granted (400,000) in the settlement.
- Confirm the warrant exercise price ($1.32) and the 5-year expiration term.
- Review the Company's latest 10-K or 10-Q to assess the dilution impact of these new securities on existing shareholders.
- Check subsequent filings to determine if the Company exercises its right to refuse piggy-back registration rights for these shares.
- Confirm the dismissal status of the Superior Court of California case (Lander v. Calidi Biotherapeutics, Inc.).